Last reviewed · How we verify
Mepolizumab 750 — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Mepolizumab 750 (Mepolizumab 750) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mepolizumab 750 TARGET | Mepolizumab 750 | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mepolizumab 750 CI watch — RSS
- Mepolizumab 750 CI watch — Atom
- Mepolizumab 750 CI watch — JSON
- Mepolizumab 750 alone — RSS
Cite this brief
Drug Landscape (2026). Mepolizumab 750 — Competitive Intelligence Brief. https://druglandscape.com/ci/mepolizumab-750. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab